Outcomes

The evidence base for GLP-1 receptor agonist outcomes is limited in the provided literature, with most studies focusing on related compounds or comparative analyses rather than direct GLP-1 efficacy data.

Metabolic Outcomes

One completed Phase 3 trial (NCT00518882) examined liraglutide, a GLP-1 receptor agonist, added to ongoing treatment for blood glucose control in Type 2 diabetes patients. However, specific outcome measures and results are not detailed in the available evidence.

A target trial emulation study compared GLP-1 receptor agonist plus SGLT2 inhibitor combination therapy versus monotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and Type 2 diabetes. The study design suggests investigation of hepatic and glycemic outcomes, but specific measurable results are not provided in the available abstracts.

Cardiovascular Outcomes

A systematic review and meta-analysis examined long-term cardiovascular benefits comparing metabolic and bariatric surgery versus pharmacological therapies (including GLP-1 receptor agonists) in patients with Type 2 diabetes and obesity. While this suggests cardiovascular outcome data exists for GLP-1 therapies, the specific biomarker changes, event rates, or symptom improvements are not detailed in the available evidence.

Safety Profile

Real-world safety data comes from a pharmacovigilance study of tirzepatide (a dual GLP-1/GIP receptor agonist) using the FAERS database, indicating monitoring of adverse events in clinical practice. However, specific safety outcomes and event rates are not provided.

Evidence Limitations

The strength of evidence is insufficient to draw definitive conclusions about GLP-1 outcomes. The provided literature lacks detailed outcome measures, effect sizes, statistical significance data, and sample sizes necessary for a comprehensive outcomes assessment. Most studies appear to be preliminary reports or abstracts without full results reporting.

This summary is based solely on limited available evidence. Consult published full-text studies and clinical guidelines for complete outcome data before making treatment decisions.

GLP-1

Member access required